Computational Software delivers assay data management platform.May 7, 2009 -
Used for high throughput screening (HTS) and high content screening (HCS) analysis, Genedata Screener® v7.0 combines enterprise-wide assay data management platform with processing workflows and flexible analysis tools. Open and scalable enterprise solution can be integrated with any plate-based HCS instrument or image analysis software and supports complex, multiplexed assay formats and technologies. Data from multiple read-outs can be compared and combined visually and statistically.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
Genedata AG
Maulbeerstrasse 46
Basel, , CH-4016
Switzerland
Genedata Screener 7.0 High Throughput Screening (HTS) and High Content Screening (HCS) Analysis Platform Released
Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced the release of Genedata Screener® 7.0, the latest version of its open and scalable enterprise solution for high throughput screening (HTS) and high content screening (HCS) analysis. Screener 7.0 combines an enterprise-wide assay data management platform with high-performance processing workflows and flexible analysis tools and provides access to high content screening-specific functionality.
Screener 7.0 can be easily integrated with any plate-based high content screening (HCS) instrument or image analysis software, including image databases via the HCS Image API. Currently it is fully compatible with the Thermo Scientific Cellomics Store image management system and integration with additional platform technology providers will follow.
Other features improve Screener's support of complex, multiplexed assay formats and technologies, such as HCS, label-free and multiplex target assays. Data from multiple read-outs can easily be compared and combined both visually and statistically, in scatter and distribution plots, statistical tables, and user-definable calculations across read-outs. New functionality also enables the consistent generation of hit lists from such assays, exploiting their multiple read-outs in a concise fashion, documenting the criteria applied and managing the results centrally for shared access.
"Genedata Screener has a history of providing the most statistically sound processing of extremely large and complex data sets and yet retains a very user-friendly interface for visualization, management and review," said Dr. Othmar Pfannes, CEO of Genedata. "As we enter the realm of increasingly complex time series and high content assay data, Genedata is proud to remain at the forefront of technology innovation."
About Genedata
Genedata develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata's solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan. For more information, please visit www.genedata.com
Contact
Allison Kurz
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com
|
|
|
|
|
|
|
| 
